Received May 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
blood clot in both lungs; This serious case was reported by a consumer via interactive digital media and described the occurrence of pulmonary thrombosis in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, less than a week after receiving Arexvy, the patient experienced pulmonary thrombosis (Verbatim: blood clot in both lungs) (serious criteria GSK medically significant). The outcome of the pulmonary thrombosis was not reported. It was unknown if the reporter considered the pulmonary thrombosis to be related to Arexvy. The company considered the pulmonary thrombosis to be unrelated to Arexvy. Additional Information: GSK Receipt Date: 26-MAY-2025 Patient took RSV shot and developed blood clots in both lungs and an unspecified enlargment within a week.; Sender's Comments: Pulmonary thrombosis is an unlisted event which is considered unrelated to GSK vaccine Arexvy